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Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response
to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS).
Methods: Four hundred seventy-three people with MS provided one or more dried blood spot samples. Information
about coronavirus disease 2019 (COVID-19) and vaccine history, medical, and drug history were extracted from ques-
tionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS-CoV-2. Antibody
titers were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the
odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wal-
lis) following the SARS-CoV-2 vaccine according to disease modifying therapy. We used regression modeling to
explore the effect of vaccine timing, treatment duration, age, vaccine type, and lymphocyte count on vaccine
response.
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Results: Compared to no disease modifying therapy, the use of anti-CD20 monoclonal antibodies (odds ratio = 0.03,
95% confidence interval [CI] = 0.01–0.06, p < 0.001) and fingolimod (odds ratio = 0.04; 95% CI = 0.01–0.12) were
associated with lower seroconversion following the SARS-CoV-2 vaccine. All other drugs did not differ significantly
from the untreated cohort. Both time since last anti-CD20 treatment and total time on treatment were significantly
associated with the response to the vaccination. The vaccine type significantly predicted seroconversion, but not in
those on anti-CD20 medications. Preliminary data on cellular T-cell immunity showed 40% of seronegative subjects had
measurable anti-SARS-CoV-2 T cell responses.
Interpretation: Some disease modifying therapies convey risk of attenuated serological response to SARS-CoV-2 vacci-
nation in people with MS. We provide recommendations for the practical management of this patient group.
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Individuals with inflammatory neurological disorders havefaced considerable uncertainty during the coronavirus dis-
ease 2019 (COVID-19) pandemic, related to both the poten-
tial risks posed by their underlying medical disorder, and the
immunomodulatory treatment needed to manage their dis-
ease. Factors that appear to confer increased vulnerability for
poor outcomes following symptomatic COVID-19 include
advanced disability, obesity, male sex, and the use of immu-
nosuppressive drugs, in particular, anti-CD20 monoclonal
antibodies.1 As a result, people with chronic neurological dis-
ease in several countries were advised to strictly self-isolate
during periods of high community transmission.
The development of effective vaccines against
COVID-19 infection, which are safe for use in vulnerable
groups, offer hope for a reduction in COVID-19 related
mortality and morbidity. However, uncertainties remain
over vaccine efficacy for those taking immunosuppressive
and/or immunomodulatory drugs, including multiple scle-
rosis (MS) disease modifying therapies (DMTs). Previous
studies have demonstrated a blunted vaccine response in
people with MS receiving ocrelizumab2 and fingolimod3;
however, vaccine responses to a truly novel biological anti-
gen (ie, one giving rise to human disease, rather than key-
hole limpet hemocyanin [KLH]) have only been subject
to limited study. Data are urgently required on the effi-
cacy of COVID-19 vaccination for those individuals
receiving immunomodulating drugs to guide them regard-
ing risks related to reopening policies, and to inform policy
around booster vaccinations4 or additional strategies for
those who are unable to respond adequately to the vaccina-
tion. There may be the potential to optimize vaccination
response in people receiving MS DMTs, for example, by
temporarily suspending continuous DMT or extending the
interval between intermittent DMTs. However, adopting
this approach in the absence of supportive evidence needs
to be balanced against unnecessary and potentially disabling
MS disease activity.
The study of MS treatment offers a relatively unique
opportunity. People with MS tend to remain on a contin-
uous platform (ie, non-induction) of DMTs for many
years, rather than having treatment “holidays” or breaks,
due to the irreversible nature of disease-related disability.
In addition, DMTs are given as monotherapy, rather than
in combination, as is practice in some other autoimmune
diseases and selected hematological malignancies. Further-
more, untreated people with MS are generally considered
to have a “normal” immune response to vaccination. As a
result, response to vaccination in people with MS offers
an opportunity to understand the role of individual medi-
cations, and their mode(s) of action on the development
of an adequate vaccine response.
In this study, we investigate the effect of MS DMTs
on the serological response to the COVID-19 vaccination
in a large multicenter cohort. Remotely patient-collected,
posted dried blood spots were used to obtain samples from
people with MS for antibody evaluation following vaccina-
tion. By establishing the antibody response to COVID-19
vaccines in relation to patient, treatment, and vaccine
characteristics we aim to better inform future guidance for
people with MS on vaccination policy, DMT manage-
ment, and infection protection.
Methods
People with MS from 5 UK MS centers (Cardiff, New-
port, Nottingham, Royal London Hospital [Barts Health
NHS Trust], and Swansea) were invited to participate in
this study. Samples were analyzed in 2 laboratories: the
University Hospital of Wales (UHW), Cardiff and the
Queen Mary University of London (QMUL).
Participants
Potential participants under the care of 5 MS clinics were
approached either in person at the time of scheduled
appointments, in writing by email or letter, or by adver-
tisement, asking them to provide one or more dried blood
spot samples along with a questionnaire, providing data
on isolation behavior, employment setting, clinical or
laboratory-confirmed cases of COVID-19 infection, vac-
cine dates, and vaccine type. Potential participants were
approached between November 2020 and June 2021,
including people with MS on all DMTs, regardless of
their decision regarding vaccination. Where participants
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agreed to take part, they were provided with a kit for self-
sampling. Participants also provided consent for access to
their medical records by study staff, allowing verification
of MS diagnosis, and details of DMT prescription, includ-
ing date of initiation and most recent administration.
Hospital records were also used to confirm all cases of
COVID-19 requiring hospital admission, and to extract
laboratory results, such as total lymphocyte counts from
routine blood monitoring data. All participants provided
written informed consent to take part in this study. This
study has Research Ethics Committee approval (REC
20/SW/0104 and 20/NE/0176).
Sample Collection
Dried blood spot sampling was undertaken remotely,
avoiding the need for phlebotomist time and hospital
visits by potentially immunosuppressed patients. A kit
containing instructions on how to collect samples, lan-
cets to obtain capillary blood, a blood spot collection
device (PerkinElmer 226 Spot Saver or Whatman
903 Protein Saver card), and a return mail envelope was
posted to participants at their home address. Participants
were asked to date their dried blood spot test card and
return it using first class surface mail as soon as possible.
Samples received at the UHW were stored desiccated at
20C until analysis; those received at QMUL were
stored at room temperature for a maximum of a week
prior to spot punching and elution, with subsequent
storage at 20C.
T cell responses to SARS-CoV-2 in 16 participants
with negative humoral response to SARS-CoV-2 were
measured using a commercially available whole blood
assay (ImmunoServ Ltd.), as previously described.5 Briefly,
10 ml venous blood from each patient was collected into
sodium heparin vacutainers (BD) and processed in the
laboratory within 6 hours of blood draw.
Antibody Testing for SARS-CoV-2 in Dried Blood
Spot Specimens
Dried blood spots were used to determine serological sta-
tus in two laboratories; 376 in UHW and 97 in QMUL.
In UHW, samples were analyzed with the COVID-
SeroKlir 2-step enzyme-linked immunosorbent assay
(ELISA; Kantaro Biosciences, USA - supplied by EKF
Diagnostics, UK), which detects SARS-CoV-2 specific
IgG antibodies against the receptor-binding domain
(RBD)6,7 using resuspended dried blood spots, using pre-
viously validated methods.8 A 6 mm diameter sub-punch
was taken from each dried blood spot using a DELFIA
dried blood spot Puncher (PerkinElmer) and placed into
2 ml 96-well plates (Waters #186002482) containing
600 μl of the Kantaro Kit sample diluent (equivalent to
1:100 dilution recommended for the Kantaro kit). The
96-well plates were then covered and shaken at room
temperature for 1 hour (as we have shown previously this
to be the optimum time to ensure complete extraction of
the blood from the filter paper collection device). The
plates were then stored at 4C until analysis (usually
within 72 hours), although extracted samples were stable
for at least 1 week. One hundred microliters of the dried
blood spot eluate were transferred to the 96-well ELISA
plate and analyzed on an automated platform (DSX;
Dynex Technologies, USA) according to the manufac-
turer’s instructions.
The Kantaro assay relies on an assay-specific calibra-
tor to report the ratio of the specimen absorbance to the
calibrator absorbance to calculate a cutoff index value.
The antibody level in plasma / serum is reported as posi-
tive (≥0.7) or negative (<0.7). In a series of paired plasma
and dried blood spots (n = 22 antibody negative and
n = 25 antibody positive samples), we observed good
agreement between paired specimens (r = 0.994) and the
gradient of the slope was 1.241x. Based upon the negative
bias observed in dried blood spot versus paired plasma
samples, we calculated the following cutoff index for dried
blood spot specimens – positive (≥0.56) and negative
(<0.56). Quality controls (QCs) as supplied by the manu-
facturer and in-house prepared dried blood spot QCs
(positive and negative) were analyzed on each assay plate.
At QMUL, samples were analyzed using the
Globody technique,9 with the RBD as the target antigen.
A 4 mm blood spot punch was eluted in 200 μl of 1%
Triton X-100 in phosphate-buffered saline (PBS) at room
temperature overnight. Eluted samples were assayed the
next day or stored at 20C until analysis. Assays were
carried out using 20 μl of dried blood spot eluate mixed
with 30 μl of a 50% slurry of Protein G agarose equili-
brated in PBS (Thermo Fisher Scientific), made up to a
final volume of 1.2 ml with 0.05% PBS-Tween 20 (PBST)
and left for 30 minutes on a rotating wheel at room tem-
perature. A PBST wash was performed by pelleting the
agarose at 200  g for 1 minute, aspirating supernatant
down to 100 μl and washing with 1,100 μl PBST. After
washing, an additional 200  g for 1 minute spin was per-
formed and aspiration of non-agarose bound mixture to
100 μl. RBD-GloBody preparation (8.7 μl) of 1  108
lux units was added to each sample and then made up to
750 μl with PBST and left on rotating wheel for
30 minutes, after which the agarose resin was applied to a
Pierce 0.8 ml centrifuge column (Thermo Fisher Scien-
tific). Columns were washed 5 times with 750 μl PBST to
remove unbound RBD-GloBody and followed by a final
wash with 750 μl PBS. Bound IgG and RBD-GloBody in
complex with IgG were eluted from spin column with the
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addition of 100 μl of 0.1 M Glycine, pH 2.7, and neutral-
ized with 12 μl 0.1 M Tris pH 9.0. Assays on 30 μl of the
resulting eluate were performed in triplicate using
furimazine substrate (20 μl furimazine in 1 ml 0.1%
bovine serum albumin [BSA] in PBS; Promega). Lumines-
cence was measured on a CLARIOstar plate reader. A
limit of blank (LoB) was determined by LoB = mean
luminescence:blank +2.58 (standard deviation:blank),
values greater than this suggest seroconversion with a con-
fidence of 99%.
Detection of SARS-CoV-2-Specific T Cell
Responses
Whole blood samples were aliquoted into microcentrifuge
tubes (Thermo Fisher Scientific) containing pre-aliquoted
peptides spanning covering the entire spike (S1 and S2)
protein (S), nucleocapsid phosphoprotein (NP), and mem-
brane glycoprotein (M). Additional tubes containing
phytohemagglutinin-L (Sigma) or nothing were run along-
side as positive and negative controls, respectively. Whole
blood samples were incubated at 37C for 20 to 24 hours.
Plasma was harvested from the top of each blood sample
the amount of IFN-γ in each sample quantified. A previ-
ously defined positive SARS-CoV-2-specific T cell
response has a cutoff value of >23.55 pg/ml IFN-γ and
50% above the negative (unstimulated) control value, dif-
ferentiating naïve controls from prior COVID-19 vaccina-
tion and/or previously infected subjects (sensitivity of
93.6% and specificity of 80.8%).5
Statistical Analysis
Participants were categorized according to DMT exposure
status at the time of the first COVID-19 vaccination. People
were considered exposed if they had received alemtuzumab
or cladribine within 4 years, ocrelizumab within 12 months,
natalizumab within 8 weeks, fingolimod, dimethyl fumarate,
teriflunomide, glatiramer acetate, or beta-interferon within
4 weeks of their vaccine first dose. All other participants were
categorized as unexposed to DMT.
Fishers exact test was used to compare the chance of
seroconversion following the first and second vaccine dose
across different DMTs. Univariate logistic regression with
FIGURE 1: Flow chart illustrating recruitment and selection of the study cohort.
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no DMT as the reference group was used across DMT
groups to provide odds ratio (OR) of seroconversion by
DMT class. Due to the different laboratory approaches
used to determine antibody titer, quantitative vaccine
responses from each laboratory were partitioned into
tertiles with no DMT as the reference group. Kruskal
Wallis test was used to compare the proportion of vaccine
responses in each tertile between DMT following the
second vaccine.
The impact of time between last dose of anti-CD20
monoclonal antibody (ocrelizumab and rituximab, excluding
ofatumumab given different administration schedule) and first
vaccine dose, and odds of seroconversion, was established
using univariate logistic regression. Similar analyses were per-
formed in order to establish the impact of time since treat-
ment initiation on odds of seroconversion. Linear regression
across tertiles with the same outputs was performed in order
to explore the impact on quantitative vaccine response.
Finally, stepwise multivariate logistic regression was
used to model the likelihood of a positive antibody
response to COVID-19 vaccine measured after the second
vaccine dose. Two groups of interest were selected for the
study - (1) those either not on DMT, or taking DMT
shown not to influence seroconversion in the univariate
analyses, and (2) those who had been treated with anti-
CD20 monoclonal antibodies. Samples from people
taking fingolimod were excluded from these analyses. An
initial model, including gender and vaccine type, was
generated; subsequently age, Expanded Disability Status
Scale (EDSS; grouped into 0.0–4.0, 4.5–5.5, 6.0–6.5, and
7.0–10.0), previous COVID-19 symptoms, time between
vaccine doses, time from second vaccine to sampling, total
























All participants 140:106 (57%) 280:150 (65%) NA 107:80 (57%)c 113:37 (75%)c
No DMT 77:18 (81%) 85:7 (92%) 1 (reference) 27:2 (93%) 41:0 (100%)
Anti-CD20 mAbd 7:45 (13%) 33:101 (25%) 0.03 (0.01–0.06)e 16:57 (22%) 11:24 (31%)
Natalizumab 23:8 (74%) 56:5 (92%) 0.92 (0.28–3.05) 28:2 (93%) 25:2 (93%)
Alemtuzumab 14:4 (78%) 24:4 (86%) 0.49 (0.13–1.83) 14:3 (82%) 9:1 (90%)
Dimethyl fumarate 9:7 (56%) 35:3 (92%) 0.96 (0.23–3.93) 12:3 (80%) 14:0 (100%)
Cladribine 1:7 (13%) 16:4 (80%) 0.33 (0.09–1.26) 5:3 (63%) 9:1 (90%)
Glatiramer acetate 2:0 (100%) 3:0 (100%) NAf NAg NAg
Fingolimod 4:15 (21%) 12:24 (33%) 0.04 (0.01–0.12)e 5:10 (33%) 4:9 (31%)
Interferon beta 3:0 (100%) 5:1 (83%) 0.41 (0.04–4.03) NAg NAg
Teriflunomide 0:2 (0%) 3:0 (100%) NAf NAg NAg
p < 0.0001 p < 0.0001
aTotal n = 187 with samples following vaccine 2 and vaccine type available.
bTotal n = 150 with samples following vaccine 2 and vaccine type available.
cDirect comparison not performed as groups not equivalent; subgroup comparisons subject to multiple testing concerns and therefore not performed.
dOcrelizumab, rituximab, and ofatumumab.
eThe p < 0.0001 using Univariate logistic regression with no DMT as the reference group was used across DMT groups to provide odds ratio of sero-
conversion by DMT class.
fLogistic regression limited by small numbers.
gData not presented as interpretation limited by small numbers.
AZ = Astra Zeneca; CI = confidence interval; DMT = disease modifying therapy; mAb = monoclonal antibody; NA = not applicable; nCoV =
novel coronavirus; OR = odds ratio.
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time on most recent DMT, and lymphocyte count were
added to the model in a stepwise manner. Only those fac-
tors shown to significantly improve model fit were
retained in the final model. Mann–Whitney U test was
used to compare potential influence on anti-SARS-CoV-2
IgG titer according to vaccine type.
Statistical analysis was performed in Stata version
16 (Stat Corp. Ltd.).
Results
One thousand three hundred seventy-five kits were sent
out across all sites between November 2020 and June
2021. A total of 1,231 (89.5%) participants returned at
least one sample (Fig 1). Participants returning at least
one dried blood spot sample following vaccination were
considered for inclusion in this analysis based on time of
sample post-vaccination (aiming for 4–8 weeks post-vacci-
nation) and quality of sample provided.
Of the 473 participants eligible for inclusion in this
analysis, 58 participants provided samples prior to vaccina-
tion, 246 during the interval between their first and
second vaccine doses, and 430 following the second
vaccine dose. Demographic and clinical features are given
in Supplementary Table S1, and are provided by DMT in
Supplementary Table S2. Participants not receiving DMT
were, on average, older and more disabled than those on
DMT (see Supplementary Table S2). Those with an
unknown vaccination type (or no vaccination) were more
likely to have missing EDSS.
Participants received their initial vaccine dose between
December 8, 2020, and June 9, 2021. Vaccine type was
available in 404 (85.4%) participants; 180 reported vaccina-
tions with BNT162b2 (Pfizer-BioNTech) mRNA vaccine,
and 224 reported vaccinations with adenoviral vector vaccine
(223 participants received ChAdOx1 nCoV-19 [Oxford–
AstraZeneca], and one received Johnson & Johnson). One
participant reported initial vaccination with the ChAdOx1
nCoV-19 (Oxford–AstraZeneca) adenoviral vector vaccine
with the second vaccine dose BNT162b2 mRNA (Pfizer-
FIGURE 2: Violin plot illustrating anti-SARS-CoV-2 antibody response following complete COVID-19 vaccine course, according to
DMT. The plot shows distribution of results according to tertiles, using the “no DMT” group as a reference. Circle indicates
median, bold line indicates interquartile range. (A) All samples (B) seropositive samples only. COVID-19 = coronavirus disease
2019; DMT = disease modifying therapy; SARS-CoV-2 = severe acute respiratory syndrome-coronavirus 2.








No DMT 84:5 (94%) 2:1 (66%) NS
Anti-CD20 mAba 25:59 (30%) 8:42 (16%) NS
Natalizumab 48:2 (96%) 8:3 (73%) 0.04
Alemtuzumab 22:1 (96%) 3:2 (60%) NS
Dimethyl fumarate 27:2 (93%) 8:1 (89%) NS
Cladribine 8:1 (89%) 8:3 (73%) NS
Glatiramer acetate 3:0 (100%) NA -
Fingolimod 12:21 (36%) 0:3 (0%) NS
Interferon beta 5:1 (83%) NA -
Teriflunomide 3:0 (100%) NA -
aOcrelizumab, rituximab, and ofatumumab.
DMT = disease modifying therapy; mAb = monoclonal antibody;
NA = not applicable; NS = not significant; QMUL = Queen Mary
University of London.
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BioNTech); this participant was excluded from analyses
using vaccine type as a variable. Median interval between
vaccine doses was 10.0 weeks (range = 3.0–14.0 weeks,
interquartile range [IQR] = 6.1–11.0 weeks).
Pre-Vaccine Serology
Of the 58 vaccine naïve baseline samples, 6 (10.3%) were
seropositive and 52 (89.7%) seronegative for SARS-CoV2.
Of the 6 participants who were seropositive at baseline;
4 were on DMT (1 was on glatiramer acetate, 1 was on
alemtuzumab [year 1 only; April 2019], and 2 were on
ocrelizumab). Data on prior symptoms suggestive of
COVID-19 was available for 44 out of 58 participants,
including all 6 who were seropositive at baseline. Only
3 out of 6 seropositive participants reported prior symp-
toms or prior positive SARS-CoV-2 polymerase chain reac-
tion (PCR). Eleven (19.2%) of the 52 individuals who
were seronegative at baseline self-reported prior symptoms
suggestive of COVID-19 (of whom 3 had confirmatory
SARS-CoV-2 PCR). There was no significant association
between patient-reported historical COVID-19 infection
and baseline seropositivity.
Post-Vaccine Serology
Overall, 140 of 246 (56.9%) participants with a sample
available between the first and second vaccine doses demon-
strated a positive IgG response (Table 1), and 280 of
430 (65.1%) at >4 weeks post second dose. Univariate logis-
tic regression demonstrated that, compared to no DMT, the
use of anti-CD20 monoclonal antibodies (OR = 0.03, 95%
confidence interval [CI] = 0.01–0.06, p < 0.001) and
fingolimod (OR = 0.04, 95% CI = 0.01–0.12) were associ-
ated with lower seroconversion following vaccine 2 (see
Table 1). All other DMTs did not differ significantly from
the untreated cohort. Subgroup analysis between the UHW
and QMUL analyzed cohorts did not demonstrate any sig-
nificant difference between the response to complete vaccina-
tion course in any DMT that passed the multiple testing
threshold (Table 2).
One-way analysis of variance (ANOVA) to examine
the effect of DMT on antibody titer was limited by ceiling
TABLE 3. Factors Predicting Serostatus Following Vaccine Dose 2 in Best Performing Model
Control group Test group OR (95% CI)
DMT No impact on vaccine response in univariate
modela
Anti-CD20 mAbb 0.03 (0.01–0.06)c
Vaccine type AstraZeneca Pfizer 2.65 (1.27–5.52)d
Gender Female Male 1.08 (0.49–2.41)
Age 1.03 (1.00–1.06)e
Prior COVID symptoms No COVID symptoms Prior COVID symptoms 1.00 (0.31–3.18)
EDSS EDSS 0.0–4.0 EDSS 4.5–5.5 2.28 (0.52–10.04)
EDSS 6.0–6.5 0.63 (0.18–2.14)
EDSS 7.0–10.0 0.27 (0.03–2.86)
Days from anti-CD20b to vaccine Anti-CD20 mAbb 1.00 (0.99–1.01)
Total time on DMT 1.00 (0.00–1.00)
Lymphocyte count 1.15 (0.68–1.95)
Time between vaccine doses 1.00 (0.89–1.14)
Time between vaccine and sample 0.85 (0.73–0.99)e
aIncludes no DMT, natalizumab, alemtuzumab, dimethyl fumarate, cladribine, glatiramer acetate, interferon beta, and teriflunomide.
bOcrelizumab and rituximab; ofatumumab excluded.
cp < 0.001.
dp < 0.01.
ep = 0.04; NS on correction for multiple testing.
CI = confidence interval; COVID-19 = coronavirus disease 2019; DMT = disease modifying therapy; EDSS = Expanded Disability Status Scale;
mAb = monoclonal antibody; OR = odds ratio.
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effects in the UHW cohort and small numbers in treat-
ment groups when restricting to the QMUL cohort.
Using tertiles defined by antibody titers in the untreated
cohort, Kruskal Wallis equality of populations rank test
demonstrated a significant difference between populations
in IgG titer tertile between DMT (Fig 2). This persisted
FIGURE 3: Violin plot illustrating anti-SARS-CoV2 antibody response following complete COVID-19 vaccine course, according to vaccine
type. The plot shows distribution of results according to tertiles, using the “noDMT” group as a reference. The circle indicates median, and
the bold line indicates interquartile range. Astra Zeneca: ChAdOx1 nCoV-19 (Oxford–AstraZeneca), Pfizer: BNT162b2 mRNA (Pfizer-
BioNTech) vaccine. (a) People who had received anti-CD20 monoclonal antibodies. (b) All other DMT (fingolimod excluded).
COVID-19 = coronavirus disease 2019; DMT = disease modifying therapy; nCov = novel coronavirus; SARS-CoV-2 = severe acute
respiratory syndrome-coronavirus 2.
TABLE 4. T-Cell Response According to Clinical/ Demographic Features
Participant DMTs
Time since DMT





1 Alemtuzumab 5 42 AstraZeneca Positive 26.0 6.9
2 Fingolimod 85 38 AstraZeneca Negative 41.0 34.9
3 Fingolimod 95 39 Pfizer Negative 25.2 19.0
4 Fingolimod 53 50 Pfizer Negative 30.1 29.6
5 Fingolimod 86 50 Pfizer Negative 8.2 <7.8
6 Fingolimod 24 51 AstraZeneca Negative 22.9 20.1
7 Fingolimod 76 43 AstraZeneca Positive 46.5 <7.8
8 None N/a 59 AstraZeneca Positive 244.9 <7.8
9 Ocrelizumab 23 48 Pfizer Negative 14.7 <7.8
10 Ocrelizumab 20 58 Pfizer Negative <7.8 <7.8
11 Ocrelizumab 21 26 Pfizer Positive 236.5 13.0
12 Ocrelizumab 9 48 Pfizer Positive 38.3 <7.8
13 Ocrelizumab 21 50 Pfizer Positive 49.7 <7.8
14 Ocrelizumab 22 56 Pfizer Positive 731.5 16.8
15 Rituximab 58 41 AstraZeneca Negative 51.6 34.7
16 Rituximab 133 57 AstraZeneca Negative 35.5 31.4
aTime in months from the commencement of named DMT to the date of first COVID-19 vaccination.
bA positive SARS-CoV-2-specific T cell response was defined as an IFN-gamma response >23.55 pg/ml and 50% above the negative (unstimulated)
control value, as previously determined.5
COVID-19 = coronavirus disease 2019; DMT = disease modifying therapy; SARS-CoV-2 = severe acute respiratory syndrome-coronavirus 2.
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regardless of whether both seropositive and seronegative
samples were included in the analysis (Fig 2A,
p = 0.0001), or if the analysis was restricted to only the
seropositive cohort (Fig 2B, p = 0.0022).
Neither time since the last anti-CD20 treatment nor
the total time on anti-CD20 DMT predicted (binary)
serostatus after the second vaccine, however, the small
number of seropositive individuals limited the power in this
analysis. Five of 72 people treated with anti-CD20 thera-
pies within the 5 months (150 days) prior to the initial vac-
cination mounted a response following the second vaccine
dose, compared to 5 of 9 people treated ≧7 months
(210 days) prior to initial vaccination (p = 0.037, Fishers
exact test). Linear regression across tertiles, excluding a sin-
gle outlier, was performed in the anti-CD20 cohort. In this
analysis, both time from last treatment administration to
initial vaccination (p = 0.033) and total time on treatment
(p = 0.025) demonstrated a significant relationship with
serological response to vaccination.
DMT type was then dichotomized into anti-
CD20 monoclonal antibody (ocrelizumab, rituximab,
and ofatumumab) and control MS with normal vaccine
response (no DMT, natalizumab, alemtuzumab, dimethyl
fumarate, cladribine, glatiramer acetate, interferon beta, and
teriflunomide). These DMTs all demonstrated a statistically
similar serological response to vaccination. Samples from
fingolimod treated individuals were excluded from this
analysis. In order to develop a multivariate regression
model, a stepwise multivariate regression model was devel-
oped. Factors retained in the final, best performing model
were vaccine type and treatment (anti-CD20 vs others).
Although the time between administration of the second
vaccine dose and age showed significance on initial testing,
they did not pass the threshold for multiple testing on
Bonferroni correction (p = 0.005; Table 3). Overall IgG
levels were not included in this analysis as only 4 of
473 participants had levels below the lower limit of normal.
Finally, the impact of vaccine type on SARS-CoV-2-IgG
titer was examined across DMT groups (anti-CD20 vs
others). There was no difference between the serological
response to the vaccination according to vaccine type in
those who had received anti-CD20 monoclonal anti-
bodies (Fig 3A; p = 0.39). However, in the control
group, those who were vaccinated with the BNT162b2
mRNA (Pfizer-BioNTech) vaccine had a significantly
greater IgG response to vaccination than those vaccinations
with the ChAdOx1 nCoV-19 (Oxford–AstraZeneca)
vaccine (Fig 3B; p < 0.0001).
T-Cell Response
The absence of a serological response to vaccination may
seem explicable when B cell (anti-CD20) targeted
therapies are used. The T-cell response to SARS-CoV2
was tested in 16 participants, all of whom had negative
humoral response after a full course of COVID-19 vacci-
nation. A positive T-cell response was observed in 40% of
these subjects: 1 participant who received alemtuzumab
5 months earlier, 1 participant not receiving DMT, 1 of
6 people receiving fingolimod, 4 of 6 people receiving
ocrelizumab, and 0 of 2 people receiving rituximab
(Table 4).
Discussion
The COVID-19 pandemic may transition to endemic
infection, but the consequences are likely to continue for
years to come. The rapid development of vaccines offers
hope for a reduction in illness severity and viral transmis-
sion, with consequent lifting of restrictions. This study
answers some of the questions that have arisen around
vaccine efficacy in people with MS taking immunomodu-
latory drugs. With a cohort of almost 500 patients, we
have demonstrated that both DMT type and vaccine type
affect humoral immune response to the COVID-19
vaccination, offering an opportunity to provide advice about
infection-prevention and control for people at risk. However,
certain DMTs, including some with high MS treatment
efficacy, appear to have no effect on the response to the
COVID-19 vaccination.
Our results align with a previous, smaller study,10
showing attenuated response to the BNT162b2 mRNA
(Pfizer-BioNTech) vaccine in people with MS receiving
ocrelizumab and fingolimod. The number of patients in
our cohort allows us to interpret results with more cer-
tainty, examine the impact of dosing time, and importantly
understand the impact of vaccine type. Anti-CD20 mono-
clonal antibodies were the DMTs most strongly associated
with lack of seroconversion following the COVID-19 vacci-
nation. Their high efficacy and relatively favorable safety
profile has offered a welcome addition to the MS DMT
landscape; however, once ocrelizumab is commenced, rapid
and profound B-cell depletion occurs, with few people
repopulating B-cells prior to their 6 months interval infu-
sion.11,12 These drugs have previously been shown to be
associated with attenuated humoral response to recall and
novel vaccinations.2 This presents an opportunity to test
people on anti-CD20 DMTs for evidence of secondary
antibody deficiency by routinely measuring Ig classes, and
also by measuring functional immunity to vaccines for
which normative reference ranges exist, for example, pneu-
mococcus and haemophilus.13 The intact T cell response in
4 of 6 vaccine nonresponders on ocrelizumab provides
some potential reassurance to those who have received the
vaccine close to their infusion time.
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We also found that fingolimod, a sphingosine-
1-phospohate (S1P) receptor modulator, is associated with
both a substantially attenuated humoral response to the
COVID-19 vaccination and a low number of T cell
responders in the vaccine nonresponders. This does not
reflect the moderately attenuated vaccine responses seen
in clinical trials,14 but has been previously demonstrated
in smaller real-world studies of COVID-19 vaccine
response.10 Given the substantial MS rebound/reactivation
associated with fingolimod cessation,15 medication with-
drawal to facilitate successful vaccination is associated with
significant risk if there is no managed switch to an alterna-
tive DMT. This strategy carries additional complexities,
including the potential for carryover DMT-associated risk,
for example, lymphopenia, and uncertainties over how to
manage a switch back if appropriate. It seems likely that
the attenuated vaccine response seen with fingolimod is a
class effect that will be seen in other S1P products includ-
ing siponimod and ponesimod; however, the different
half-lives of these medications means that drug-specific
studies are needed.
Our data offers the opportunity to tailor advice for
people with MS who are at risk of attenuated humoral
response to vaccination. Our study suggested that
delaying commencement of fingolimod or anti-CD20
DMT should be considered in new starters, to allow
time for vaccination. Our data did not demonstrate a
relationship between delaying established anti-CD20
infusions and improving seroconversion but this analysis
is likely to have been underpowered. We did demon-
strate a modest (but significant) impact of delaying
established anti-CD20 infusions on COVID-19 antibody
titer, raising questions over whether substantially
extended dosing intervals to allow B-cell recovery might
enhance vaccine response. The proportion of individuals
who seroconverted increased between vaccine 1 and 2, in
keeping with studies in the healthy control population,16
supporting the use of a booster vaccination, particularly
for those who may have had an attenuated response to
the initial vaccination. However, further study is required
to determine whether the booster vaccination induces
humoral immunity in all those who failed to mount a
humoral response to the first course. It is not yet routine
to test anti-SARS-CoV-2 antibodies in clinical practice,
but knowledge of seronegative status in people with MS
may allow more vigilant infection control precautions,
for example, continuing to socially distance and ensuring
that household contacts are vaccinated, and may also
allow individualized treatment of emergent COVID-19
infection, for example, monoclonal antibodies to SARS-
CoV-2 have been shown to benefit those who are
seronegative.17
Our overall finding of a differential humoral response
according to vaccine type replicates data in healthy control
cohorts,18 but was not replicated in people on anti-CD20
DMT. Whereas this provides no current rationale for rec-
ommending one vaccine type over another in those at risk
of an attenuated response, this is deserving of further study
given potential limitations of power. Current evidence sug-
gests that heterologous vaccine regimens may elicit stronger
antibody and T-cell responses.19,20 The effect of age on
vaccine response in this cohort is in line with data from the
general population,16 and may be entirely due to age-related
immunosenescence,18 or there may be an additional impact
from collider bias related to age, disability progression, and
DMT choice.
This study made use of dried blood spot sampling,
reducing the need for potentially vulnerable people to
attend healthcare facilities during the pandemic as well as
reduced costs for phlebotomist time and equipment.
Dried blood spot sampling has been used since the 1960s
for neonatal screening for inborn errors of metabolism,21
but wider medical uses, including serological screening of
IgG levels,22,23 have proven particularly useful during the
COVID-19 pandemic.24 Whereas extensive work was
undertaken to develop and validate the assays used in this
study, the lack of a gold standard for RBD assay develop-
ment was a potential limitation; because a true negative
result was defined based on historical samples. In order to
increase the power for this study, samples were analyzed
in 2 laboratories and data were pooled. The assay used in
the UHW laboratory was subject to significant ceiling
effects, with around a third of untreated patients having
samples with an IgG titer at or above ceiling. Although sub-
group analysis demonstrated similar seroconversion between
the 2 assays, and the use of tertiles avoided pooling
2 nonlinear scales, this represents a potential limitation of
the study. Reports of vaccine type and dates, as well as prior
COVID-19 infection were self-reported in this study, intro-
ducing the possibility of inaccuracy. A further caveat is that
whereas all DMT exposures were part of monotherapy regi-
mens, some people with MS had been exposed sequentially
to several therapies. Given the large number of DMTs, we
were not powered to explore the effect of sequential thera-
pies, so it cannot be wholly excluded.
Pre-vaccine samples were only available for 58 of
473 participants in this study, of whom 10% had serologi-
cal evidence of prior infection. The lack of full concor-
dance between pre-vaccine serology and history of
previous COVID-19 infection is not unexpected and is
likely to reflect a combination of asymptomatic infections
(those seropositive pre-vaccine), and either unproven
COVID-19 (lack of laboratory confirmation) or decline of
anti-SARS-CoV-2 antibodies following proven COVID-
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19 (those seronegative at baseline).25 It is likely that in the
full cohort who provided post-vaccine samples, at least a
similar proportion of all participants already had anti-
SARS-CoV-2 antibodies at baseline. There is evidence of
an association between the presence of antibodies to
SARS-CoV-2 at the time of vaccination and a greater sub-
sequent immune response to the COVID-19 vaccine.26
Given the lack of association between prior reported
COVID-19 symptoms and baseline seropositivity in this
cohort, we did not feel confident to use this as a marker
of prior infection to explore enhanced vaccine response.
SARS-CoV-2 is a strongly immunogenic virus that
can induce antigen-specific antibody production in the
majority of infected patients.27 However, the immune cor-
relates of protection following COVID-19 vaccines have
not yet been fully established. Antibody responses to
COVID-19 vaccination appear to be protective.28 Specifi-
cally, anti-SARS-Cov-2 RBD IgG levels appear to corre-
late with virus neutralization titres,29–31 and durable
antibody responses have been shown to be associated with
more rapid recovery from infection.32 In animal models,
neutralizing antibody (NAb) levels following vaccination
using the spike antigen correlate with protection against
SARS-CoV-2,33,34 and antibody dependent functional
immunity is enhanced by a COVID-19 vaccine.35
Although NAbs are frequently considered a key compo-
nent of the immune response after viral infection, anti-
viral T cell mediated immunity is also central to viral
clearance.36 SARS-CoV-2-specific CD4+ and CD8+ T
cells have been associated with milder disease in acute and
convalescent individuals.37 We measured T-cell responses
to SARS-CoV-2 in a small subcohort of people with a
negative antibody response to COVID-19 vaccines in this
study. The preliminary data demonstrated that 40% of
people with negative serological response did nevertheless
mount a measurable T-cell response. Ongoing/future
work on magnitude and durability of immune response
required to protect from COVID-19 is needed in this and
other cohorts, including whether a booster vaccination
improves the chance of seroconversion in people with
attenuated immune response to the initial vaccination,
and the relative importance of both humoral and T cell
immunity in terms of symptomatic and severe infection.
Crucially, it will be important to monitor the population
who are seronegative yet demonstrate strong T cell
responses, to understand how these responses wane over
time, and whether these subjects are protected from future
SARS-CoV-2 infections.
In conclusion, this study demonstrates the impact of
DMT type, vaccine type, and age on the vaccine response. It
provides high quality evidence to support advice for people
with MS, and indicates routes for future study, including the
need for clinical trials to guide advice around balancing risks
and potential benefits of suspending or delaying treatment.
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